Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results
May 08 2017 - 04:01PM
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, announced today that the Company will host a conference
call and live audio webcast on Monday, May 15, 2017 at 5:00 p.m. ET
to report its first quarter 2017 financial results and provide a
corporate update.
In order to participate in the conference call, please dial
877-303-6235 (domestic) or 631-291-4837 (international) and refer
to conference ID 18632775. The live webcast can be accessed under
"Events & Presentations" in the Investors and Media section of
the Company's website at www.fatetherapeutics.com. The archived
webcast will be available on the Company's website beginning
approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders. The Company’s hematopoietic cell
therapy pipeline is comprised of NK- and T-cell immuno-oncology
programs, including off-the-shelf product candidates derived from
engineered induced pluripotent cells, and immuno-regulatory
programs, including product candidates to prevent life-threatening
complications in patients undergoing hematopoietic cell
transplantation and to promote immune tolerance in patients with
autoimmune disease. Its adoptive cell therapy programs are based on
the Company’s novel ex vivo cell programming approach, which it
applies to modulate the therapeutic function and direct the fate of
immune cells. Fate Therapeutics is headquartered in San Diego, CA.
For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2023 to Mar 2024